For Research Use Only. Not for human consumption. The following is a structural and biochemical comparison based on published preclinical literature. It does not address dosing, combination use, or recommendations for use.
Two Peptides, Frequently Confused
BPC-157 and TB-500 are two of the most-searched research peptides on the market, and they are routinely discussed together, sold together in blends, and compared on forums almost interchangeably. Structurally and biochemically, they are unrelated molecules. They come from different parent proteins, have different amino acid sequences and molecular weights, and, based on the published preclinical literature, appear to act through different mechanisms. This comparison lays out the chemistry directly: sequence, synthesis, stability, published research findings, and the analytical methods used to verify identity and purity.
Sequence and Molecular Data
BPC-157 is a synthetic pentadecapeptide, a chain of 15 amino acids, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV). It carries the molecular formula C₆₂H₉₈N₁₆O₂₂ and a molecular weight of approximately 1,419.5 g/mol (PubChem CID 9941957), with CAS number 137525-51-0. Five of its fifteen residues are proline, an unusually high proportion that is directly relevant to the stability profile discussed below.
TB-500, as commercially supplied, is a synthetic fragment of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid regulatory protein found in nearly all human and animal cell types. The fragment is built around the LKKTETQ motif, the segment of the parent protein established in the literature as its actin-binding domain, typically supplied as the N-acetylated sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln. “TB-500” is a research-community name rather than a standardized chemical designation, and different suppliers use it to describe either this shorter fragment or the full 43-residue Tβ4 sequence — the molecular weight and formula figures are not interchangeable between the two, so any comparison should confirm which version a given source means. BPC-157 has no equivalent ambiguity: its sequence and molecular weight are settled across the literature and supplier data.
Synthesis and Stability
Both compounds are produced by solid-phase peptide synthesis (SPPS), the standard method for building short peptide chains residue by residue, and both are supplied as lyophilized (freeze-dried) powder. Where they diverge is stability behavior. BPC-157’s proline-rich sequence is associated with an unusually well-documented resistance to enzymatic and acidic degradation — published research describes the parent compound as stable across a wide pH range, including gastric-acid conditions that break down most peptides almost immediately, a property attributed to proline’s ring structure resisting the cleavage patterns most digestive proteases rely on (Pharmaceutics, 2026).
Summary of Published Preclinical Research
A 2016 study published in the Journal of Molecular Medicine examined BPC-157’s effect on blood vessel formation using a chick chorioallantoic membrane (CAM) assay, endothelial tube-formation assays in human vascular endothelial cells, and a rat hind-limb ischemia model. The authors reported increased vessel density in both the in-vitro and in-vivo assays, along with increased expression and internalization of vascular endothelial growth factor receptor 2 (VEGFR2) in the treated tissue and cell cultures (PubMed, PMID 27847966). This VEGFR2-associated signaling pathway is among the most frequently cited mechanistic findings in the BPC-157 literature. Separately, one of the earliest and most-cited BPC-157 animal studies examined rats with surgically transected Achilles tendons, using histological and biomechanical analysis of the tendon tissue during recovery (PubMed, PMID 14554208).
The foundational biochemical characterization of Thymosin Beta-4 comes from in-vitro biophysical work showing that it binds monomeric G-actin in a 1:1 complex, sequestering it and inhibiting polymerization into filamentous (F-)actin (Safer et al., Journal of Biological Chemistry, 1991, PMID 1999398). A later structural biology study used X-ray crystallography to resolve how the sequence physically binds actin, mapping the interaction to helices at the barbed and pointed faces of the actin monomer (Xue & Robinson, PNAS, 2014). Separately, a 1999 study in the Journal of Investigative Dermatology applied Thymosin Beta-4 topically to full-thickness excisional wounds in a rat model and evaluated wound closure rate, re-epithelialization, and markers of collagen deposition and angiogenesis compared to vehicle-treated controls (PubMed, PMID 10469335).
The Mechanistic Distinction That Matters Most
Based on this literature, BPC-157’s most consistently described mechanism runs through VEGFR2-mediated angiogenic signaling, while Thymosin Beta-4/TB-500’s most consistently described and structurally verified mechanism is direct, physical G-actin sequestration through the LKKTETQ motif. These are two distinct biochemical pathways studied by two different research literatures — the peptides are not interchangeable, mechanistically or structurally, even though they are frequently sold and discussed as a pair. As with most peptide research, a definitive, universally accepted mechanism has not been established for either compound, and the pathways described above are drawn from animal and cell-culture models rather than confirmed human pharmacodynamics.
Analytical Verification
Because BPC-157 and TB-500 are structurally distinct molecules with different, non-overlapping molecular weights, they are independently verifiable using the same two analytical methods applied across our catalog. HPLC (High-Performance Liquid Chromatography) separates a sample into its components and reports what percentage corresponds to the primary compound peak, the basis of the purity percentage on each lot’s Certificate of Analysis. LC-MS (Liquid Chromatography–Mass Spectrometry) confirms molecular identity by measuring the compound’s mass, which should match the expected weight for that specific sequence — approximately 1,419.5 g/mol for BPC-157, and the value specific to the synthesized fragment for TB-500. See our Quality & Testing page for a fuller explanation of how HPLC and LC-MS testing work.
Research Use Only / Handling Note
Both compounds are intended strictly for in-vitro and laboratory research applications by qualified personnel, and both are supplied as lyophilized powder. Neither compound is intended for human or veterinary administration, and neither is a finished pharmaceutical product.
Why This Comparison Doesn’t Answer “Which One Should I Use”
This page is limited to the chemistry of BPC-157 and TB-500 and the preclinical literature describing each compound individually. FDA warning letters issued to other research-peptide sellers, including Summit Research Peptides and USApeptide.com, found that surrounding content describing intended human outcomes, recommended combinations, or safety profiles for personal use undermined a “Research Use Only” label, regardless of how the products themselves were labeled. For that reason, this page intentionally does not address combining the two compounds, dosing either one, or any safety question tied to human or animal use. Researchers with questions along those lines should direct them to a qualified institutional or medical professional, not a vendor content page.